BNET Industries

Market Cap:$150.4B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Pfizer and B.C. launch $9M collaboration to tackle cancer
-
Reportlinker Adds Growth Factors Blood And Tissue - A World Report
-
Barclays appoints US lev loan syndicate head - memo
-
Pfizer signs agreement with Protalix BioTherapeutics for Taliglucerase alfa
-
Pfizer Inc. PFE JOBS Acquires Rights to Protalix Biotherapeutics's Gaucher Drug in Deal Worth $115M
-
Roche's Merger Formula for Genentech
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
Pfizer Inc. and Wyeth; Analysis of Agreement Containing Consent Order To Aid Public Comment and...
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
-
FDA panel backs Pfizer's anti-infection vaccine for kids
-
Cash Just Kept On Piling Up, But It Looks Like The Spending Has Started
-
Goldman Sachs Said Pfizer PFE Best Positioned US Pharma in China
-
EDITORIAL: Difficult mix of business, science
-
$75M verdict unsealed in Prempro-cancer case
-
Sanofi-Aventis on hunt for Boston partners
News & Analysis
Filter by
merger and pfizer inc. - All News and Analysis
As Tax Breaks for Pfizer End, Jobs Disappear
As Pfizer PFE reorganizes after its merger with Wyeth, municipalities are finding that the tax deals they once struck to keep the drug giant in town are having short-term advantages at best and, at worst, no effect at all. Pfizer must make 19,500 layoffs across its empire to make the...
In Pfizer-Wyeth Merger Suit, It's Capitalism v. Socialism
The suit filed by various pharmacies to block the Pfizer-Wyeth merger is worth reading if you want to put in context the sheer size of the merger. It also delineates a faux conflict between the forces of capitalism pharmacies and socialism drug companies. by Jim Edwards
Pfizer Q1 2009 Earnings Call Transcript
Question-and-Answer SessionOperator Thank you. Operator Instructions. And our first question comes from Catherine Arnold of Credit Suisse. Please proceed. Catherine Arnold - Credit Suisse Thanks very much. Good morning. Jeffrey Kindler Good morning. Catherine Arnold - Credit Suisse Good Morning. I wanted to ask you two things. One, could...
Pfizer Director Whose Stock Sold Ahead of Wyeth Merger: "I Sometimes Know Too Much''
What are we to make of the Bloomberg report that Pfizer director James Kilts sold $259,772 of his shares in the company around the same time Pfizer began negotations to acquire Wyeth? In acquisitions, the buying company's stock usually declines because its cash is being spent on...
Post Merger, Pfizer-Wyeth Might Be Structured Like J&J
When Pfizer and Wyeth complete their merger, the new company might look a bit like Johnson & Johnson: a collection of relatively small units working autonomously. That scenario emerged in a chat over a cup of tea that BNET had yesterday at Pfizer's New York HQ with...
Will Pfizer-Wyeth Merger Force Chief Justice Roberts Off Preemption Case?
Lawyers for Wyeth have informed the US Supreme Court of the merger with Pfizer, in case the justices now have a conflicts in Wyeth v. Levine. Chief Justice John Roberts usually recuses himself in cases regarding Pfizer, according to the Mass Tort Litigation Blog. He owns Pfizer...
Reaction to Pfizer-Wyeth: Employees Despair, Plot Rebellion; Analysts Shrug; PFE Stock Down 10%
Reaction to the Pfizer-Wyeth merger is ... mixed, to say the least. Pfizer employees think this will be Pharmacia/Warner-Lambert redux. Wall Street analysts are all over the place. Pfizer's stock has lost 10 percent of its value between the opening bell and lunchtime. Wyeth's...
PFIZER INC - Final Results.
Pfizer Fourth-Quarter and Full-Year 2005 Financial Results Reflect Operating and Financial Strength ...
PFIZER INC - Merger Update.
Pfizer Expects Acquisition of Vicuron Pharmaceuticals to Close on September 14, 2005 ...
US authorities clear Sanofi takeover offer for Aventis
WASHINGTON AFP ? US regulatory authorities conditionally agreed to accept the pending merger of French-German pharmaceutical group Aventis and its smaller French rival Sanofi-Synthelabo into the world's third-largest pharmaceutical group. The Federal Trade Commission agreed to the merger on the condition that the two companies give up key drug...
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes

